Philly Fights Cancer

In a landmark moment for immune-based therapies, AbbVie is acquiring Capstan Therapeutics—a biotech startup launched from the University of Pennsylvania—for $2.1 billion. The move underscores growing confidence in in-vivo CAR-T technology, an innovative way to reprogram immune cells directly inside the body.

Capstan’s work builds on the groundbreaking CAR-T therapy pioneered at Penn by Dr. Carl June, which has already transformed cancer treatment for countless patients. Traditional CAR-T involves removing a patient’s T cells, engineering them in a lab, and then reinfusing them—a complex, time-intensive, and costly process. Capstan’s approach aims to streamline this into a single injection powered by mRNA and lipid nanoparticles, similar to the technology used in COVID-19 vaccines.

While Capstan is first focusing on autoimmune diseases, the implications for cancer care are profound. By simplifying treatment and reducing costs, this approach could one day make life-saving therapies more accessible to patients everywhere. With AbbVie’s global resources, Capstan is poised to accelerate trials and move closer to bringing these cutting-edge therapies to the people who need them most.

For Philly Fights Cancer, this story comes full circle. Our mission has always been to raise funds and awareness for the very research that began here in Philadelphia—and that research is now shaping the future of cancer treatment worldwide. Every breakthrough like this proves that the work happening at Penn, and the support of our community, brings us closer to a cancer-free world.

Learn more about this important progress at the link below.

Link: Penn start-up Capstan acquired by AbbVie for $2.1 billion